Clinical Trial Update: AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD4573 as monotherapy or in combination for relapsed/refractory peripheral T-cell lymphoma and relapsed/refractory classical Hodgkin l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• AZD4573

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-08-28